Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 533

1.

Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.

Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ.

J Gastroenterol Hepatol. 2014 Jan;29(1):102-9. doi: 10.1111/jgh.12329.

PMID:
23829453
2.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466
3.

Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.

Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Wang LY, Huang JF, Juo SH, Lin YC, Dai CY, Chuang WL, Yu ML.

J Gastroenterol Hepatol. 2013 Sep;28(9):1515-20. doi: 10.1111/jgh.12211.

PMID:
23560893
4.

Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.

Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K.

J Gastroenterol Hepatol. 2012 Sep;27(9):1467-72. doi: 10.1111/j.1440-1746.2012.07129.x.

PMID:
22432893
5.

Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.

Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y.

World J Gastroenterol. 2015 Apr 7;21(13):3904-11. doi: 10.3748/wjg.v21.i13.3904.

6.

Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.

Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D'Avolio A.

Arch Virol. 2015 Aug;160(8):2009-17. doi: 10.1007/s00705-015-2482-3. Epub 2015 Jun 10.

PMID:
26060059
7.

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.

Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.

PMID:
24102823
8.

Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.

Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Enomoto N, Inao M, Tanaka A, Kaito M, Imazeki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsuhashi H, Izumi N, Kudo M; RETRY Study Group.

Dig Dis. 2012;30(6):554-60. doi: 10.1159/000343064. Epub 2012 Dec 13.

PMID:
23258094
9.

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.

Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.

11.

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T.

J Gastroenterol. 2014 Apr;49(4):737-47. doi: 10.1007/s00535-013-0824-z. Epub 2013 May 21.

PMID:
23689988
12.

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M.

Hepatology. 2012 Feb;55(2):336-42. doi: 10.1002/hep.24683. Epub 2012 Jan 3.

PMID:
21932415
13.

KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.

Umemura T, Ota M, Katsuyama Y, Wada S, Mori H, Maruyama A, Shibata S, Nozawa Y, Kimura T, Morita S, Joshita S, Komatsu M, Matsumoto A, Kamijo A, Kobayashi M, Takamatsu M, Yoshizawa K, Kiyosawa K, Tanaka E.

Hum Immunol. 2014 Aug;75(8):822-6. doi: 10.1016/j.humimm.2014.06.003. Epub 2014 Jun 11.

PMID:
24929144
14.

Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.

Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML.

Sci Rep. 2015 Jul 1;5:11710. doi: 10.1038/srep11710.

15.

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.

Heo NY, Lim YS, Lee W, Oh M, An J, Lee D, Shim JH, Kim KM, Lee HC, Lee YS, Suh DJ.

Clin Mol Hepatol. 2014 Jun;20(2):177-84. doi: 10.3350/cmh.2014.20.2.177. Epub 2014 Jun 30.

16.

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.

Shimada N, Toyoda H, Tsubota A, Ide T, Takaguchi K, Kato K, Kondoh M, Matsuyama K, Kumada T, Sata M.

J Gastroenterol. 2014 Nov;49(11):1485-94. doi: 10.1007/s00535-013-0918-7. Epub 2013 Nov 28.

PMID:
24287582
17.

Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.

Jung YK, Kim JH, Ahn SM, Yang JW, Park SJ, Kim JW, Yeon JE, Kwon OS, Kim YS, Choi DJ, Kim JH, Byun KS.

J Clin Gastroenterol. 2013 Aug;47(7):644-50. doi: 10.1097/MCG.0b013e3182896abf.

PMID:
23442843
18.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
19.

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.

Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN.

BMC Infect Dis. 2015 Mar 26;15:156. doi: 10.1186/s12879-015-0888-x.

20.

Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.

Susser S, Herrmann E, Lange C, Hamdi N, Müller T, Berg T, Perner D, Zeuzem S, Sarrazin C.

PLoS One. 2014 Nov 13;9(11):e112592. doi: 10.1371/journal.pone.0112592. eCollection 2014.

Supplemental Content

Support Center